785 related articles for article (PubMed ID: 26616410)
1. Incidence of Clostridium difficile infection in patients receiving high-risk antibiotics with or without a proton pump inhibitor.
Gordon D; Young LR; Reddy S; Bergman C; Young JD
J Hosp Infect; 2016 Feb; 92(2):173-7. PubMed ID: 26616410
[TBL] [Abstract][Full Text] [Related]
2. The evaluation of Clostridium difficile infection (CDI) in a community hospital.
Daniel A; Rapose A
J Infect Public Health; 2015; 8(2):155-60. PubMed ID: 25301221
[TBL] [Abstract][Full Text] [Related]
3. Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.
Kurti Z; Lovasz BD; Mandel MD; Csima Z; Golovics PA; Csako BD; Mohas A; Gönczi L; Gecse KB; Kiss LS; Szathmari M; Lakatos PL
World J Gastroenterol; 2015 Jun; 21(21):6728-35. PubMed ID: 26074711
[TBL] [Abstract][Full Text] [Related]
4. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure.
Stevens V; Dumyati G; Brown J; Wijngaarden E
Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1035-42. PubMed ID: 21833992
[TBL] [Abstract][Full Text] [Related]
5. Implementation of Global Strategies to Prevent Hospital-Onset Clostridium difficile Infection: Targeting Proton Pump Inhibitors and Probiotics.
Lewis PO; Lundberg TS; Tharp JL; Runnels CW
Ann Pharmacother; 2017 Oct; 51(10):848-854. PubMed ID: 28821215
[TBL] [Abstract][Full Text] [Related]
6. Regional differences in Clostridium difficile infections in relation to fluoroquinolone and proton pump inhibitor use, Finland, 2008-2011.
Kanerva M; Ollgren J; Voipio T; Mentula S; Lyytikäinen O
Infect Dis (Lond); 2015 Aug; 47(8):530-5. PubMed ID: 25832317
[TBL] [Abstract][Full Text] [Related]
7. High morbidity and mortality of Clostridium difficile infection and its associations with ribotype 002 in Hong Kong.
Wong SH; Ip M; Hawkey PM; Lo N; Hardy K; Manzoor S; Hui WW; Choi KW; Wong RY; Yung IM; Cheung CS; Lam KL; Kwong T; Wu WK; Ng SC; Wu JC; Sung JJ; Lee N
J Infect; 2016 Aug; 73(2):115-22. PubMed ID: 27246801
[TBL] [Abstract][Full Text] [Related]
8. Proton Pump Inhibitors and the Risk for Hospital-Acquired Clostridium difficile Infection.
Barletta JF; El-Ibiary SY; Davis LE; Nguyen B; Raney CR
Mayo Clin Proc; 2013 Oct; 88(10):1085-90. PubMed ID: 24012413
[TBL] [Abstract][Full Text] [Related]
9. Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection.
McDonald EG; Milligan J; Frenette C; Lee TC
JAMA Intern Med; 2015 May; 175(5):784-91. PubMed ID: 25730198
[TBL] [Abstract][Full Text] [Related]
10. Effects of proton pump inhibitor use on risk of Clostridium difficile infection: a hospital cohort study.
Park YH; Seong JM; Cho S; Han HW; Kim JY; An SH; Gwak HS
J Gastroenterol; 2019 Dec; 54(12):1052-1060. PubMed ID: 31187275
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Clostridium difficile infections in patients receiving antimicrobial and acid-suppression therapy.
King RN; Lager SL
Pharmacotherapy; 2011 Jul; 31(7):642-8. PubMed ID: 21923450
[TBL] [Abstract][Full Text] [Related]
12. Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients.
Ro Y; Eun CS; Kim HS; Kim JY; Byun YJ; Yoo KS; Han DS
Gut Liver; 2016 Jul; 10(4):581-6. PubMed ID: 27021503
[TBL] [Abstract][Full Text] [Related]
13. Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis.
Oshima T; Wu L; Li M; Fukui H; Watari J; Miwa H
J Gastroenterol; 2018 Jan; 53(1):84-94. PubMed ID: 28744822
[TBL] [Abstract][Full Text] [Related]
14. Medication risk factors associated with healthcare-associated Clostridium difficile infection: a multilevel model case-control study among 64 US academic medical centres.
Pakyz AL; Jawahar R; Wang Q; Harpe SE
J Antimicrob Chemother; 2014 Apr; 69(4):1127-31. PubMed ID: 24327619
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors and risk for recurrent Clostridium difficile infection.
Linsky A; Gupta K; Lawler EV; Fonda JR; Hermos JA
Arch Intern Med; 2010 May; 170(9):772-8. PubMed ID: 20458084
[TBL] [Abstract][Full Text] [Related]
16. Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.
Faleck DM; Salmasian H; Furuya EY; Larson EL; Abrams JA; Freedberg DE
Am J Gastroenterol; 2016 Nov; 111(11):1641-1648. PubMed ID: 27575714
[TBL] [Abstract][Full Text] [Related]
17. Risk of Clostridium difficile infection in hospitalized patients receiving metronidazole for a non-C difficile infection.
Rodriguez S; Hernandez MB; Tarchini G; Zaleski M; Vatanchi M; Cardona L; Castro-Pavia F; Schneider A
Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1856-61. PubMed ID: 24681079
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitors and diarrhoea related to Clostridium difficile infection in hospitalised patients: a case-control study.
Leonard AD; Ho KM; Flexman J
Intern Med J; 2012 May; 42(5):591-4. PubMed ID: 22616966
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients.
Barletta JF; Sclar DA
Crit Care; 2014 Dec; 18(6):714. PubMed ID: 25540023
[TBL] [Abstract][Full Text] [Related]
20. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting.
Dalton BR; Lye-Maccannell T; Henderson EA; Maccannell DR; Louie TJ
Aliment Pharmacol Ther; 2009 Mar; 29(6):626-34. PubMed ID: 19183143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
